CAS: 1357470-29-1; 8-Cyclopentyl-2-((4-(4-Methylpiperazin-1-yl)Phenyl)Amino)-7-Oxo-7,8-Dihydropyrido[2,3-D]Pyrimidine-6-Carbonitrile

该化合物是一种选择性的单子依赖性动脉抑制器,正在对其潜在的肿瘤治疗应用进行调查. 它针对参与细胞循环监管的特定的CDK, 展示出临床前研究中充满希望的活动. 纳拉帕西里氏菌展示了CDK4/6的高度选择性,这可能会比更广泛的光谱CDK抑制剂减少非目标影响. 它的行动机制包括破坏不受控制的细胞扩散,使它成为治疗某些癌症的候选对象,特别是由CDK4/6发育调节驱动的癌症. 早期研究显示,它具有有利的药用植物特性和可控毒性特征. 进一步临床评估正在进行,以评估其对人类试验的效果和安全性.

结构式图片

合成工艺路线路线简述

    📜4-氨基-2-甲巯基嘧啶-5-甲醛置于sodium Hydride,溶剂黄146,间氯过氧苯甲酸,苄胺体系中,用 二氯甲烷,N,N-二甲基甲酰胺,甲苯 用作溶剂,化学反应 11.08H,反应生成8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈
    参考文献:Discovery Of 8-Cyclopentyl-2-[4-(4-Methyl-Piperazin-1-yl)-Phenylamino]-7-Oxo-7,8-Dihydro-Pyrido[2,3-D]Pyrimidine-6-Carbonitrile (7X) As A Potent Inhibitor Of Cyclin-Dependent Kinase 4 (Cdk4) And Ampk-Related Kinase 5 (Ark5)
    标题:Discovery Of 8-Cyclopentyl-2-[4-(4-Methyl-Piperazin-1-yl)-Phenylamino]-7-Oxo-7,8-Dihydro-Pyrido[2,3-D]Pyrimidine-6-Carbonitrile (7X) As A Potent Inhibitor Of Cyclin-Dependent Kinase 4 (Cdk4) And Ampk-Related Kinase 5 (Ark5)
    摘要:The Success Of Imatinib,A Bcr-Abl Inhibitor For The Treatment Of Chronic Myelogenous Leukemia,Has Created A Great Impetus For The Development Of Additional Kinase Inhibitors As Therapeutic Agents. However,The Complexity Of Cancer Has Led To Recent Interest In Polypharmacological Approaches For Developing Multikinase Inhibitors With Low Toxicity Profiles. With This Goal In Mind,We Analyzed More Than 150 Novel Cyano Pyridopyrimidine Compounds And Identified Structure-Activity Relationship Trends That Can Be Exploited In The Design Of Potent Kinase Inhibitors. One Compound,8-Cyclopentyl-2[-4-(4-Methyl-Piperazin-L-yl)-Phenylamino]-7-Oxo-7,8-Dihydro-Pyrido[2,3-D]Pyrimidine-6-Carbonitrile (7X),Was Found To Be The Most Active,Inducing Apoptosis Of Tumor Cells At A Concentration Of Approximately 30-100 Nm. In Vitro Kinase Profiling Revealed That 7X Is A Multikinase Inhibitor With Potent Inhibitory Activity Against The Cdk4/cyclin D1 And Arks Kinases. Here,We Report The Synthesis,Structure-Activity Relationship,Kinase Inhibitory Profile,In Vitro Cytotoxicity,And In Vivo Tumor Regression Studies By This Lead Compound.
    Doi:10.1021/jm401073P

    海关参考信息

    专利信息


    专利号:US-9359298-B2
    优先权日:2011-12-23
    标题:Cajanine structure analogous compound, preparation method and use
    发明人:LI ZHUORONG; JI XINGYUE; Xue situ; ZHENG GUANGHUI; LI YUHUAN; TAO PEIZHEN; JIANG JIANDONG
    权利人:INST MED BIOTECHNOLOGY CAMS
    摘要:Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Divakar SK, Ramana Reddy MV, Cosenza SC, Baker SJ, Perumal D, Antonelli AC, Brody J, Akula B, Parekh S, Premkumar Reddy E. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2015 Jul 15. doi: 10.1038/leu.2015.185. [Epub ahead of print] doi: 10.1158/1535-7163.MCT-13-0847. Epub 2014 Feb 25.
    3: Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J. 2013 Jan;15(1):250-7. doi: 10.1208/s12248-012-9428-4. Epub 2012 Nov 22.

    合成参考文献


    参考文献:10.1038/s41598-024-59650-y
    摘要:Yang T, Ke H, Liu J, An X, Xue J, Ning J, Hao F, Xiong L, Chen C, Wang Y, Zheng J, Gao B, Bao Z, Gong K, Zhang L, Zhang F, Guo S, Li QX. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. Sci Rep. 2024 Apr 19;14(1):9032.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知